Melanotan I
Symbol M1 · MW 1647 Da
Linear α-MSH analog approved as Scenesse for erythropoietic protoporphyria.
- Discovered
- 1980
- Half-life
- 15 hours
- Approval
- Approved (Scenesse — rare condition)
Reported effects
- Photoprotection
- Pigmentation
- UV tolerance
Overview
Melanotan I, also known as Afamelanotide, is a melanocortin peptide associated with melanin production and skin pigmentation. It works by activating pathways that increase melanin, the pigment responsible for darker skin tone and natural UV defense. Afamelanotide has specific medical relevance in certain light-sensitivity conditions, but it is also commonly discussed in the cosmetic peptide space because of its pigmentation effects. Its purpose is related to melanin stimulation, photoprotection research, and skin pigmentation support. As a beauty peptide, Melanotan I is best understood as a pigmentation-focused peptide rather than a standard skincare ingredient.
How it's taken
- Typical Administration
- Injectable / Subcutaneous Implant
- Typical Dosage
- Approved afamelanotide implant dose is 16 mg; non-approved cosmetic use has no established dosage
- Typical Frequency
- Implant administered approximately every 2 months in approved medical use
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Melanotan I?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.